Tempest Therapeutics Financial Results
Tempest Therapeutics reported third quarter 2026 financial results and provided a business update on its in vivo CAR-T pipeline, including the lead candidate TPST-4903. During the quarter, the company exercised its option for an exclusive license to Senlang's CD7-targeted platform and secured access to capital through a $50 million equity line of credit and a $2.5 million private placement.
“The third quarter marked a period of meaningful progress in the advancement of two next-generation in vivo CAR-T platforms with the potential to transform treatment across multiple diseases.”
Matt Angel, Ph.D., president and chief executive officer of Tempest
“We made important strides in expanding our pipeline and strengthening our position in the rapidly evolving in vivo CAR-T landscape through our strategic collaboration with Senlang by obtaining exclusive license rights to our clinical-stage BCMA/GPRC5D in vivo CAR-T candidate TPST-4903, while securing access to additional capital to support our development priorities.”
Matt Angel, Ph.D., president and chief executive officer of Tempest